(Q54539131)

English

The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

author name string

Philipp Baumann

1

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

Carmen Junghanns

2

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

Sonja Mandl-Weber

3

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

Stefan Strobl

4

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

Fuat Oduncu

5

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

Ralf Schmidmaier

6

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

language of work or name

0 references

publication date

23 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

156

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

5

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

633-642

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Histone deacetylase inhibitors as anti-neoplastic agents.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Cancer. p53, guardian of the genome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

A work in progress: the clinical development of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The INK4 family of cell cycle inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Acetylation is indispensable for p53 activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Requirement of Hos2 histone deacetylase for gene activity in yeast

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

A fluorogenic histone deacetylase assay well suited for high-throughput activity screening

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08983.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08983.X

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22211565

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54539131&oldid=1107916340"